FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns applying urea derivatives or their pharmaceutically acceptable salts characterised by formula 
, wherein RB is specified in: 
while R3, R4, R'2, R'3, R'4, R'5, and R'6 represent hydrogen as GSK-3 inhibitors, pharmaceutical compositions containing them, and using them for treating and/or preventing disorders the development of which involves GSK-3.
EFFECT: preparing the pharmaceutical compositions containing them, and using them for treating and/or preventing disorders the development of which involves GSK-3.
14 cl, 2 ex, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| GSK-3 INHIBITORS | 2005 |
|
RU2379300C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| TACRINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | 2004 |
|
RU2402545C2 |
| SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
| HETEROCYCLIC INHIBITORS OF GLYCOGEN SYNTHASE-KINASE GSK-3 | 2001 |
|
RU2294931C2 |
| 3-AZABICYCLO[3,1,0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2510396C2 |
| USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
| LEUKOTRIENE A4-HYDROLASE INHIBITORS | 2014 |
|
RU2690489C2 |
| IMIDAZOLE DERIVATIVES ACTIVE TO CB1 RECEPTOR | 2005 |
|
RU2377238C2 |
